Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center

Yuebing Li, Adham Jammoul, Karin Mente, Jianbo Li, Robert W. Shields, Steven Vernino, Alexander Rae-Grant

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: Antibody against the acetylcholine receptor of autonomic ganglia (gAChR-Ab) is implicated in the pathogenesis of autoimmune autonomic ganglionopathy (AAG) and several other disorders. Methods: This study was a retrospective evaluation of 95 patients positive for gAChR-Ab. Results: Twenty-one (22%) patients had AAG, with a greater median gAChR-Ab level (0.21 nmol/L) and higher percentage (57%) of antibody levels >0.20 nmol/L when compared with the remaining 74 patients without autonomic manifestations (non-AAG group, 0.10 nmol/L and 15%, respectively). Only 2 new cases of malignancy were diagnosed after gAChR-Ab detection. The non-AAG group was associated with high frequencies of neurological and non-neurological autoimmunity, but also included 23 (31%) patients with mostly degenerative disorders. Conclusion: Detection of gAChR-Ab, especially at a higher level, is helpful for the diagnosis of AAG in patients with corresponding autonomic symptoms. However, its value is limited for predicting cancer risk and for diagnosis and management of patients without autonomic symptoms.

Original languageEnglish (US)
Pages (from-to)386-391
Number of pages6
JournalMuscle and Nerve
Volume52
Issue number3
DOIs
StatePublished - Sep 1 2015

Fingerprint

Cholinergic Receptors
Neurology
Tertiary Care Centers
Antibodies
Autonomic Ganglia
Risk Management
Autoimmunity
Neoplasms

Keywords

  • Autoimmune autonomic ganglionopathy
  • Autoimmunity
  • Diagnostic testing
  • Ganglionic autonomic acetylcholine receptor
  • Malignancy

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)
  • Physiology

Cite this

Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. / Li, Yuebing; Jammoul, Adham; Mente, Karin; Li, Jianbo; Shields, Robert W.; Vernino, Steven; Rae-Grant, Alexander.

In: Muscle and Nerve, Vol. 52, No. 3, 01.09.2015, p. 386-391.

Research output: Contribution to journalArticle

Li, Yuebing ; Jammoul, Adham ; Mente, Karin ; Li, Jianbo ; Shields, Robert W. ; Vernino, Steven ; Rae-Grant, Alexander. / Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center. In: Muscle and Nerve. 2015 ; Vol. 52, No. 3. pp. 386-391.
@article{afe40813949c464fbf97a6e407e4f01d,
title = "Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center",
abstract = "Introduction: Antibody against the acetylcholine receptor of autonomic ganglia (gAChR-Ab) is implicated in the pathogenesis of autoimmune autonomic ganglionopathy (AAG) and several other disorders. Methods: This study was a retrospective evaluation of 95 patients positive for gAChR-Ab. Results: Twenty-one (22{\%}) patients had AAG, with a greater median gAChR-Ab level (0.21 nmol/L) and higher percentage (57{\%}) of antibody levels >0.20 nmol/L when compared with the remaining 74 patients without autonomic manifestations (non-AAG group, 0.10 nmol/L and 15{\%}, respectively). Only 2 new cases of malignancy were diagnosed after gAChR-Ab detection. The non-AAG group was associated with high frequencies of neurological and non-neurological autoimmunity, but also included 23 (31{\%}) patients with mostly degenerative disorders. Conclusion: Detection of gAChR-Ab, especially at a higher level, is helpful for the diagnosis of AAG in patients with corresponding autonomic symptoms. However, its value is limited for predicting cancer risk and for diagnosis and management of patients without autonomic symptoms.",
keywords = "Autoimmune autonomic ganglionopathy, Autoimmunity, Diagnostic testing, Ganglionic autonomic acetylcholine receptor, Malignancy",
author = "Yuebing Li and Adham Jammoul and Karin Mente and Jianbo Li and Shields, {Robert W.} and Steven Vernino and Alexander Rae-Grant",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/mus.24559",
language = "English (US)",
volume = "52",
pages = "386--391",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Clinical experience of seropositive ganglionic acetylcholine receptor antibody in a tertiary neurology referral center

AU - Li, Yuebing

AU - Jammoul, Adham

AU - Mente, Karin

AU - Li, Jianbo

AU - Shields, Robert W.

AU - Vernino, Steven

AU - Rae-Grant, Alexander

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Introduction: Antibody against the acetylcholine receptor of autonomic ganglia (gAChR-Ab) is implicated in the pathogenesis of autoimmune autonomic ganglionopathy (AAG) and several other disorders. Methods: This study was a retrospective evaluation of 95 patients positive for gAChR-Ab. Results: Twenty-one (22%) patients had AAG, with a greater median gAChR-Ab level (0.21 nmol/L) and higher percentage (57%) of antibody levels >0.20 nmol/L when compared with the remaining 74 patients without autonomic manifestations (non-AAG group, 0.10 nmol/L and 15%, respectively). Only 2 new cases of malignancy were diagnosed after gAChR-Ab detection. The non-AAG group was associated with high frequencies of neurological and non-neurological autoimmunity, but also included 23 (31%) patients with mostly degenerative disorders. Conclusion: Detection of gAChR-Ab, especially at a higher level, is helpful for the diagnosis of AAG in patients with corresponding autonomic symptoms. However, its value is limited for predicting cancer risk and for diagnosis and management of patients without autonomic symptoms.

AB - Introduction: Antibody against the acetylcholine receptor of autonomic ganglia (gAChR-Ab) is implicated in the pathogenesis of autoimmune autonomic ganglionopathy (AAG) and several other disorders. Methods: This study was a retrospective evaluation of 95 patients positive for gAChR-Ab. Results: Twenty-one (22%) patients had AAG, with a greater median gAChR-Ab level (0.21 nmol/L) and higher percentage (57%) of antibody levels >0.20 nmol/L when compared with the remaining 74 patients without autonomic manifestations (non-AAG group, 0.10 nmol/L and 15%, respectively). Only 2 new cases of malignancy were diagnosed after gAChR-Ab detection. The non-AAG group was associated with high frequencies of neurological and non-neurological autoimmunity, but also included 23 (31%) patients with mostly degenerative disorders. Conclusion: Detection of gAChR-Ab, especially at a higher level, is helpful for the diagnosis of AAG in patients with corresponding autonomic symptoms. However, its value is limited for predicting cancer risk and for diagnosis and management of patients without autonomic symptoms.

KW - Autoimmune autonomic ganglionopathy

KW - Autoimmunity

KW - Diagnostic testing

KW - Ganglionic autonomic acetylcholine receptor

KW - Malignancy

UR - http://www.scopus.com/inward/record.url?scp=84938959903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938959903&partnerID=8YFLogxK

U2 - 10.1002/mus.24559

DO - 10.1002/mus.24559

M3 - Article

C2 - 25557122

AN - SCOPUS:84938959903

VL - 52

SP - 386

EP - 391

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

IS - 3

ER -